Rituxan Is Far Cheaper Than Other Therapy Options Over Myasthenia Gravis Patients’ Lifetimes, Study Shows

The cost of Genentech’s myasthenia gravis treatment Rituxan (rituximab) is half that of the blood purification process known as plasmapheresis and a third that of intravenous immunoglobulin therapy over a patient’s lifetime, according to a study. Few health insurance systems reimburse the costs of Rituxan for myasthenia gravis, the researchers…

Soliris Keeps Improving Myasthenia Gravis Symptoms During Extension of Phase 3 Trial

Soliris (eculizumab) continued improving myasthenia gravis patients’ muscle strength and functioning in a 52-week extension of a 26-week Phase 3 clinical trial, researchers reported. Alexion Pharmaceuticals said the extension study covered the same category of participant: patients with refractory generalized myasthenia gravis (gMG) who have anti-acetylcholine receptor (AchR) antibodies. The original Phase 3 trial…

Catalyst Readies Phase 3 Study of Firdapse in Patients with MuSK-MG

Catalyst Pharmaceuticals announced that it will soon begin a Phase 3 clinical trial to assess Firdapse (amifampridine phosphate) in people with myasthenia gravis who are positive for the MuSK antibody. In meetings, the company and the U.S. Food and Drug Administration (FDA) arrived at an agreement regarding the size, scope and objectives of…

Myasthenia Gravis Patients See Moderate Improvement with Prograf, China Study Shows

Prograf (tacrolimus) moderately improves myasthenia gravis (MG) in patients with inadequate response to glucocorticoids (GCs), a new study from China shows. The study, “Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China,” appeared in the…

Muscle Regeneration Delayed in Myasthenia Gravis As Stem Cell Functioning Is Impaired, Study Suggests

Muscle regeneration in myasthenia gravis likely is delayed as a result of the impaired functioning of muscle stem cells, called satellite cells (SCs), a study has found. The study, “Muscle satellite cells are functionally impaired in myasthenia gravis: consequences on muscle regeneration,” was published in the journal Acta Neuropathologica.

2021 Myasthenia Gravis Survey Results

BioNews Survey Infographic

Myasthenia Gravis News conducted a survey from Feb. 11-March 28 to gain greater insight into the characteristics of the MG community and disease management. Results of the survey have now been published. Click on the image to view the infographic, and click here to read the story.